Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: A study by the EORTC Soft Tissue and Bone Sarcoma Group

European Journal of Cancer

Volumn 37, Issue 7, 2001, Pages 870-877

  Judson, I ^a,l   Radford, J A ^b   Harris, M ^b   Blay, J Y ^c   Van Hoesel, Q ^d   Le Cesne, A ^e   Van Oosterom, A T ^f   Clemons, M J ^b   Kamby, C ^g   Hermans, C ^h   Whittaker, J ⁱ   Donato Di Paola, E ^h   Verweij, J ^j   Nielsen, S ^k  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c CENTRE LÉON BÉRARD   (France)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g Mental Health Services CPH   (Denmark)

^h EORTC DATA CENTER   (Belgium)

ⁱ ALZA CORPORATION   (United States)

^j ERASMUS MEDICAL CENTER   (Netherlands)

^k AARHUS UNIVERSITY HOSPITAL   (Denmark)

^l INSTITUTE OF CANCER RESEARCH   (United Kingdom)

more..

Author keywords

Doxorubicin; Liposomal doxorubicin; Soft tissue sarcoma

Indexed keywords

DOXORUBICIN; IFOSFAMIDE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER GRADING; CANCER LOCALIZATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG SAFETY; FEMALE; GASTROINTESTINAL CARCINOMA; HUMAN; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; OSTEOSARCOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOFT TISSUE SARCOMA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG CARRIERS; FEMALE; HUMANS; LIPOSOMES; MALE; MIDDLE AGED; SARCOMA; SOFT TISSUE NEOPLASMS; TREATMENT OUTCOME;

EID: 18844475615     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00050-8     Document Type: Article

References (19)

1. Doxorubicin in relapsed soft tissue sarcoma: Justification of phase II evaluation of new drugs in this disease
2. Cyclosphosphamide versus ifosfamide: A randomized phase II trial in adult soft-tissue sarcomas
3. Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: A study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
4. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: A randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
5. Chemotherapy in the multidisciplinary approach to soft tissue sarcomcas. EORTC Soft Tissue and Bone Sarcoma Group studies in perspective
6. Doxorubicin in sterically stabilized liposomes
7. Tissue distrubution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts
8. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy
9. Doxil (D) in platinum-refractory epithelial ovarian cancer (EOC): Results from three consecutive phase I/II studies
10. Doxil in patients with pretreated metastatic breast cancer (MBC): A dose-schedule finding study with pharmacokinetics
11. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: Results of a multicenter phase II trial
12. Phase I trial of dose-intensive liposome-encapsulated doxorubicin in patients with advanced sarcoma
13. Early results of a phase II study of liposomal doxorubicin (Doxil) in refractory sarcoma
14. Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group
15. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin and cisplatin against advanced soft tissue sarcomas
16. High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group
17. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: An analysis of 2,185 patients treated with anthracycline-containing first-line regimens - A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study
18. A predictive model for aggressive non-Hodgkin's lymphoma